ArticleLeukemia2026

Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy.

Umair Munawar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.